570
Participants
Start Date
March 31, 2010
Primary Completion Date
September 30, 2011
Study Completion Date
November 30, 2011
Brisdelle (paroxetine mesylate)
Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
Placebo capsules
Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
Rochester Clinical Research, Rochester
Clinical Trials Research Services, LLC, Pittsburgh
The Clinical Trial Center, LLC, Jenkintown
Philadelphia Clinical Research, Philadelphia
Virginia Women's Center, Richmond
National Clinical Research, Inc., Richmond
Hawthorne Medical Research, Inc., Winston-Salem
Hawthorne Research, Greensboro
SC Clinical Research Center, LLC, Columbia
Coastal Carolina Research Center, Mt. Pleasant
Soapstone Center for Clinical Research, Decatur
Mount Vernon Clinical Research, LLC, Sandy Springs
Comprehensive Clinical Trials, LLC, West Palm Beach
Altus Research, Lake Worth
Visions Clinical Research, Boynton Beach
Women's Medical Research Group, LLC, Clearwater
Anchor Research Center, Naples
Meridien Research, Brooksville
Montgomery Women's Health Associates, PC, Montgomery
Clinical Research Associates, Inc., Nashville
Chattanooga Medical Research, LLC, Chattanooga
Columbus Center for Women's Health Research, Columbus
Women's Clinic of Lincoln, PC, Lincoln
The Woman's Hospital of Texas Clinical Research Center, Houston
Downtown Women's Health Care, Denver
East Valley Family Physicians PLC, Chandler
Genesis Center For Clinical Research, San Diego
Apex Research Institute, Santa Ana
Women's Clinical Research Center, Seattle
North Spokane Women's Clinic Research, Spokane
Chase Medical Research, LLC, Waterbury
Phoenix Ob-Gyn Associates, LLC, Moorestown
Lead Sponsor
Noven Therapeutics
INDUSTRY